Harrow Health Inc (HROW) - Net Assets
Based on the latest financial reports, Harrow Health Inc (HROW) has net assets worth $28.35 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($419.54 Million) and total liabilities ($391.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Harrow Health Inc balance sheet assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $28.35 Million |
| % of Total Assets | 6.76% |
| Annual Growth Rate | 44.09% |
| 5-Year Change | 376.54% |
| 10-Year Change | 709.87% |
| Growth Volatility | 3821.74 |
Harrow Health Inc - Net Assets Trend (2005–2025)
This chart illustrates how Harrow Health Inc's net assets have evolved over time, based on quarterly financial data. Check how tangible is Harrow Health Inc's equity to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Harrow Health Inc (2005–2025)
The table below shows the annual net assets of Harrow Health Inc from 2005 to 2025. For live valuation and market cap data, see Harrow Health Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $52.09 Million | -24.83% |
| 2024-12-31 | $69.30 Million | -1.01% |
| 2023-12-31 | $70.00 Million | +160.38% |
| 2022-12-31 | $26.89 Million | +145.95% |
| 2021-12-31 | $10.93 Million | -59.26% |
| 2020-12-31 | $26.83 Million | -2.15% |
| 2019-12-31 | $27.42 Million | +10.78% |
| 2018-12-31 | $24.75 Million | +846.50% |
| 2017-12-31 | $2.62 Million | -59.34% |
| 2016-12-31 | $6.43 Million | +564.40% |
| 2015-12-31 | $-1.39 Million | -116.99% |
| 2014-12-31 | $8.15 Million | -46.06% |
| 2013-12-31 | $15.11 Million | +51.16% |
| 2012-12-31 | $10.00 Million | +688.02% |
| 2011-12-31 | $-1.70 Million | -63.74% |
| 2010-12-31 | $-1.04 Million | -279.87% |
| 2009-12-31 | $577.21K | -87.37% |
| 2008-12-31 | $4.57 Million | +30.98% |
| 2007-12-31 | $3.49 Million | +16247.32% |
| 2006-12-31 | $21.35K | -38.98% |
| 2005-12-31 | $34.99K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Harrow Health Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15647779400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.00K | 0.07% |
| Other Components | $208.93 Million | 398.38% |
| Total Equity | $52.45 Million | 100.00% |
Harrow Health Inc Competitors by Market Cap
The table below lists competitors of Harrow Health Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Thai Union Group PCL
BK:TU
|
$1.42 Billion |
|
Zbit Semiconductor Inc. A
SHG:688416
|
$1.42 Billion |
|
HIAG Immobilien Holding AG
SW:HIAG
|
$1.42 Billion |
|
Cpi Fim SA
WAR:OPG
|
$1.42 Billion |
|
J & J Snack Foods Corp
NASDAQ:JJSF
|
$1.42 Billion |
|
Shenzhen Hui Chuang Da Technology Co.Ltd
SHE:300909
|
$1.42 Billion |
|
Hengtong Logistic Co Ltd
SHG:603223
|
$1.42 Billion |
|
CITIC Guoan Information Industry Co Ltd
SHE:000839
|
$1.42 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Harrow Health Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 69,652,000 to 52,446,000, a change of -17,206,000 (-24.7%).
- Net loss of 5,139,000 reduced equity.
- Other factors decreased equity by 12,067,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.14 Million | -9.8% |
| Other Changes | $-12.07 Million | -23.01% |
| Total Change | $- | -24.70% |
Book Value vs Market Value Analysis
This analysis compares Harrow Health Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 29.78x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 14807.06x to 29.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $0.00 | $42.48 | x |
| 2006-12-31 | $0.24 | $42.48 | x |
| 2007-12-31 | $15.78 | $42.48 | x |
| 2008-12-31 | $12.34 | $42.48 | x |
| 2009-12-31 | $1.48 | $42.48 | x |
| 2010-12-31 | $-2.63 | $42.48 | x |
| 2011-12-31 | $-4.27 | $42.48 | x |
| 2012-12-31 | $2.22 | $42.48 | x |
| 2013-12-31 | $1.75 | $42.48 | x |
| 2014-12-31 | $0.89 | $42.48 | x |
| 2015-12-31 | $-0.14 | $42.48 | x |
| 2016-12-31 | $0.50 | $42.48 | x |
| 2017-12-31 | $0.13 | $42.48 | x |
| 2018-12-31 | $1.04 | $42.48 | x |
| 2019-12-31 | $1.05 | $42.48 | x |
| 2020-12-31 | $1.05 | $42.48 | x |
| 2021-12-31 | $0.42 | $42.48 | x |
| 2022-12-31 | $0.98 | $42.48 | x |
| 2023-12-31 | $2.16 | $42.48 | x |
| 2024-12-31 | $1.95 | $42.48 | x |
| 2025-12-31 | $1.43 | $42.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Harrow Health Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.80%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.89%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 7.62x
- Recent ROE (-9.80%) is above the historical average (-240.49%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -132.04% | 0.00% | 0.00x | 1.14x | $-49.71K |
| 2006 | -2716.37% | 0.00% | 0.00x | 1.18x | $-582.14K |
| 2007 | -122.76% | 0.00% | 0.00x | 1.21x | $-4.63 Million |
| 2008 | -72.27% | 0.00% | 0.00x | 1.17x | $-3.76 Million |
| 2009 | -788.97% | 0.00% | 0.00x | 2.90x | $-4.61 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.43 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-784.00K |
| 2012 | -53.86% | -5384.00% | 0.01x | 1.07x | $-6.38 Million |
| 2013 | -50.58% | -76431.24% | 0.00x | 1.04x | $-9.15 Million |
| 2014 | -124.14% | -609.52% | 0.16x | 1.26x | $-10.93 Million |
| 2015 | 0.00% | -163.64% | 0.69x | 0.00x | $-15.76 Million |
| 2016 | -296.75% | -95.71% | 0.73x | 4.24x | $-19.73 Million |
| 2017 | -458.32% | -44.76% | 1.12x | 9.15x | $-12.25 Million |
| 2018 | 59.09% | 35.35% | 0.84x | 2.00x | $12.15 Million |
| 2019 | 0.61% | 0.33% | 0.87x | 2.13x | $-2.60 Million |
| 2020 | -12.35% | -6.87% | 0.85x | 2.11x | $-6.08 Million |
| 2021 | -159.55% | -24.85% | 0.74x | 8.71x | $-19.14 Million |
| 2022 | -52.39% | -15.90% | 0.56x | 5.84x | $-16.77 Million |
| 2023 | -34.70% | -18.75% | 0.42x | 4.43x | $-31.45 Million |
| 2024 | -25.10% | -8.76% | 0.51x | 5.58x | $-24.45 Million |
| 2025 | -9.80% | -1.89% | 0.68x | 7.62x | $-10.38 Million |
Industry Comparison
This section compares Harrow Health Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $206,313,051
- Average return on equity (ROE) among peers: -44.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Harrow Health Inc (HROW) | $28.35 Million | -132.04% | 13.80x | $1.42 Billion |
| Aurora Cannabis Inc (ACB) | $1.68 Million | -10.54% | 0.00x | $160.23 Million |
| Akanda Corp (AKAN) | $-2.20 Million | 0.00% | 0.00x | $5.31 Million |
| Akebia Ther (AKBA) | $68.12 Million | -199.28% | 3.41x | $340.21 Million |
| Alkermes Plc (ALKS) | $1.11 Billion | -4.33% | 0.82x | $7.49 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.64 Billion |
| Amphastar P (AMPH) | $295.51 Million | -0.94% | 0.32x | $825.42 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $5.21 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-375.58 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $143.47 Million | -7.58% | 0.33x | $196.52 Million |
| ANI Pharmaceuticals Inc (ANIP) | $19.15 Million | -241.27% | 1.34x | $1.80 Billion |
About Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, in… Read more